Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy.

Abstract

BACKGROUND:

Patients with epidermal growth factor receptor 2-positive (HER2+) breast cancer and pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) may be candidates for nonoperative clinical trials if residual invasive and in situ disease are eradicated.

METHODS:

This study analyzed 280 patients with clinical T1-2N0-1 HER2+ breast cancer who underwent NST followed by surgical resection to determine key characteristics of patients with pCR in the breast and lymph nodes compared with those with residual disease.

RESULTS:

Of the 280 patients, 102 (36.4%) had pCR in the breast and lymph nodes after NST, and 50 patients (17.9%) had residual ductal carcinoma in situ (DCIS) in the breast only. For 129 patients (46.1%), DCIS was present on the pretreatment biopsy, and NST failed to eradicate the DCIS component in 64.3%. Patients with residual disease were more likely to have hormone receptor-positive (HR+) tumors than those with negative tumors (73.4% vs. 50.8%; p < 0.0001). Radiologic response (odds ratio [OR], 5.62; p = 0.002) and HR+ status (OR, 2.56; p < 0.0001) were predictive of residual disease. Combined imaging methods after NST had a sensitivity of 97.1% and a negative predictive value of 70.6% for detection of residual disease. Patients with invasive disease and DCIS shown on the pretreatment core biopsy were less likely than those without DCIS to achieve pCR in the breast (31% vs. 43%; p  = 0.038).

CONCLUSION:

The study results delineate and identify unique characteristics associated with HER2+ breast cancers that are important in selecting patients for inclusion in clinical trials assessing nonoperative management after NST, and the low negative predictive value of imaging mandates image-guided biopsy for selection.

• Authors: Susie Sun, Raquel F D van la Parra, Gaiane M Rauch, Christina Checka, Audree B Tadros, Anthony Lucci Jr, Mediget Teshome, Dalliah Black, Rosa F Hwang, Benjamin D Smith, Savitri Krishnamurthy, Vicente Valero, Wei T Yang, Henry M Kuerer
• Journal: Annals of surgical oncology (Ann Surg Oncol) Vol. 26 Issue 10 Pg. 3071-3079 (Oct 2019) ISSN: 1534-4681 [Electronic] United States
• PMID: 31342361 (Publication Type: Journal Article)

Chemical References

• ERBB2 protein, human
• Receptor, ErbB-2

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy, metabolism, pathology)
• Carcinoma, Ductal, Breast (drug therapy, metabolism, pathology)
• Carcinoma, Intraductal, Noninfiltrating (drug therapy, metabolism, pathology)
• Female
• Follow-Up Studies
• Humans
• Image-Guided Biopsy (methods)
• Lymph Nodes (pathology)
• Mastectomy (statistics & numerical data)
• Middle Aged
• Neoadjuvant Therapy (methods)
• Neoplasm, Residual (drug therapy, metabolism, pathology)
• Patient Selection
• Prognosis
• Prospective Studies
• Receptor, ErbB-2 (metabolism)